[{"address1": "4149 Liberty Canyon Road", "city": "Agoura Hills", "state": "CA", "zip": "91301", "country": "United States", "phone": "805-730-0360", "website": "https://www.acelyrin.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.", "fullTimeEmployees": 93, "companyOfficers": [{"maxAge": 1, "name": "Ms. Melanie  Gloria B.S.N.", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 667525, "exercisedValue": 0, "unexercisedValue": 668578}, {"maxAge": 1, "name": "Ms. Mina  Kim", "age": 49, "title": "CEO & Director", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilbert M. Labrucherie J.D.", "age": 51, "title": "CFO & Chief Business Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tyler  Marciniak", "title": "Head of Investor Relations & Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sanam  Pangali J.D.", "title": "Chief Legal Officer & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Suzy  Buckhalter CPA", "title": "Senior Director of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth A. Lock", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shephard  Mpofu M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia A. Turney", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.47, "open": 4.5, "dayLow": 4.43, "dayHigh": 4.64, "regularMarketPreviousClose": 4.47, "regularMarketOpen": 4.5, "regularMarketDayLow": 4.43, "regularMarketDayHigh": 4.64, "forwardPE": -2.1761906, "volume": 465692, "regularMarketVolume": 465692, "averageVolume": 1106050, "averageVolume10days": 698110, "averageDailyVolume10Day": 698110, "bid": 4.52, "ask": 4.59, "bidSize": 100, "askSize": 600, "marketCap": 466839232, "fiftyTwoWeekLow": 3.36, "fiftyTwoWeekHigh": 28.24, "fiftyDayAverage": 5.2009, "twoHundredDayAverage": 6.1263, "currency": "USD", "enterpriseValue": -187788064, "floatShares": 64304467, "sharesOutstanding": 99808304, "sharesShort": 6931103, "sharesShortPriorMonth": 6807752, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0694, "heldPercentInsiders": 0.08136, "heldPercentInstitutions": 1.00391, "shortRatio": 4.73, "shortPercentOfFloat": 0.0793, "bookValue": 5.707, "priceToBook": 0.80077106, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -299796992, "trailingEps": -1.94, "forwardEps": -2.1, "enterpriseToEbitda": 0.443, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SLRN", "underlyingSymbol": "SLRN", "shortName": "ACELYRIN, INC.", "longName": "Acelyrin, Inc.", "firstTradeDateEpochUtc": 1683207000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "331b354b-7a4d-3b82-ac00-9819e1a01b9d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.57, "targetHighPrice": 20.0, "targetLowPrice": 6.0, "targetMeanPrice": 10.5, "targetMedianPrice": 9.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 635240000, "totalCashPerShare": 6.365, "ebitda": -423561984, "totalDebt": 1309000, "quickRatio": 7.771, "currentRatio": 7.862, "debtToEquity": 0.23, "returnOnAssets": -0.3563, "returnOnEquity": -0.43789002, "freeCashflow": -160484128, "operatingCashflow": -216330000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]